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As part of ongoing studies into the isolation of antihypertensive peptides, 12 common 
macroalgae species from Azores were investigated for their potential angiotensin-
converting enzyme (ACE) inhibitory properties. After optimization of enzymatic hydrolysis 
conditions, the anti-ACE activity was determined by high performance liquid chromatog-
raphy (HPLC). The species under study include four Rhodophyta (Gelidium microdon, Os-
mundea pinnatifida, Porphyra sp. and Pterocladiella capillacea), four Chlorophyta (Chae-
tomorpha linum, Codium adhaerens, Ulva compressa and Ulva rigida) and four Heterokon-
tophyta (Cystoseira humilis, Fucus spiralis, Padina pavonica and Sargassum cymosum). 
The bromelain hydrolysates derived from P. capillacea, Porphyra sp., F. spiralis, U. com-
pressa, O. pinnatifida and U. rigida were the most active presenting an ACE inhibitory ac-
tivity of 48.73 ± 1.58%, 50.96 ± 1.82%, 56.77 ± 1.80%, 59.80 ± 0.95%, 62.59 ± 1.60% and 
65.68 ± 0.72%, respectively. These results suggest that some macroalgae from the littoral 
Azorean sea are potential sources of powerful ACE inhibitor peptides, with potential impact 
on public health, particularly on the hypertensive patients. These features make these algae 
valuable to the regional economy and may also provide an incentive for marine biodiversity 
conservation and valuation of marine algal resources. 
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matic hydrolysis, pepsin, bromelain, HPLC 
Lisete S. Paiva (e-mail: lisetepaiva@uac.pt), Elisabete M.C. Lima & José A.B. Baptista, 
CITA-A – Research Center for Agricultural Technology & Department of Technological 
Sciences and Development, University of Azores, 9501-801 Ponta Delgada, S. Miguel, 
Azores, Portugal; Lisete S. Paiva & Ana I. Neto, Marine Biology Group, Department of 
Biology, University of Azores, 9501-801 Ponta Delgada, S. Miguel, Azores, Portugal; Ana 
I. Neto, cE3c – Centre for Ecology, Evolution and Environmental Changes/ Azorean 
Biodiversity Group and University of Azores, Department of Biology, 9501-801 Ponta 
Delgada, S. Miguel, Azores, Portugal. 
 
INTRODUCTION 
Hypertension, one of the most common serious 
chronic health problems, affects about 25% of the 
world’s adult population (Mittal & Singh 2010). 
This problem of epidemic proportions carries a 
high risk factor for arteriosclerosis, stroke, myo-
cardial infarction and end-stage renal disease 
(Zhang et al. 2006). It is well known that the an-
giotensin I-converting enzyme (ACE), a zinc-
containing metalloenzyme, plays a key role in the 
control of blood pressure by the rennin-
angiotensin system (Fujita et al. 2000). It acts as 
an exo-peptidase that cleaves a dipeptide of       
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C-terminal of angiotensin I to produce the oc-
tapeptide angiotensin II, which is a potent vaso-
constrictor (Curtiss et al. 1978). Generally, ACE 
synthetic inhibitors cause a number of undesirable 
side effects, like cough, hyperkalemia, renal fail-
ure, fetal anomalies, angioedema, dysgeusia and 
skin rashes (Brown & Vaughan 1998). For this 
reason, there is a trend towards searching for nat-
ural ACE inhibitors as alternatives to synthetic 
drugs. Recently, much attention has been paid to 
the potential of marine organism constituents as 
novel therapeutic drug candidates for the treat-
ment of hypertension (e.g. Wijesekara & Kim 
2010), and some ACE inhibitory peptides have 
already been isolated from the hydrolyzates of 
algae species (e.g. Sato et al. 2002). Enzymatic 
hydrolysis has become a valuable tool for modi-
fying the functionality of proteins resulting in a 
good source of bioactive peptides that may be 
beneficial for the organism's functions (Korhonen 
et al. 1998). 
    The Azores Islands, due to their isolated loca-
tion in the middle of the Atlantic Ocean associat-
ed with a low pollution levels of their seawater 
(Neto et al. 2009), are a very promising location 
for marine natural resources that may produce 
new ingredients with medicine-like effects in 
treating or preventing certain diseases. Ongoing 
research investigates the isolation of natural anti-
hypertensive agents to search for novel ACE in-
hibitory activity peptides from marine algae (Pai-
va et al. 2014a,b). The present study analyses, for 
the first time, the in vitro ACE inhibitory proper-
ties of enzymatic hydrolysates obtained from 12 
macroalgae species which are abundant in the 
Azorean intertidal zone (Neto et al. 2006). 
MATERIAL AND METHODS 
CHEMICALS AND REAGENTS 
Acetonitrile (ACN) and Methanol (MeOH), 
HPLC grade, were purchased from Fluka Chemi-
ka (Steinheim, Switzerland). Sodium chloride 
was obtained from E. Merck (Darmstadt, Germa-
ny). Deionized water was obtained from a Milli-
pore water purification system (Millipore, Bed-
ford, MA, USA). Trizma base, zinc chloride, hip-
puric acid (HA), hippuryl-L-histidyl-L-leucine 
(HHL), hydrochloric acid (HCl) and various 
commercial enzymes, such as angiotensin I-
converting enzyme (ACE) from porcine kidney, 
bromelain (B4882), chymotrypsin (C-9381), ficin 
(F6008), pancreatin (P1750), pepsin (77161), 
peptidase (P7500), protease from Bacillus licheni-
formis (P5380), protease from Streptomyces 
griseus (P6911) and trypsin (T8003) were pur-
chased from Sigma-Aldrich (St. Louis, MO, 
USA). All other reagents used in this study were 
reagent grade chemicals. 
 
MACROALGAL COLLECTION 
All macroalgae samples used in this study were 
collected from the littoral zone of São Miguel 
Island, Azores Archipelago (37°40′ N - 25°31′ 
W), Portugal, and voucher specimens were pre-
pared and deposited in the Herbarium AZB - Ruy 
Telles Palhinha of the Department of Biology at 
the University of Azores, namely: Chaetomorpha 
linum (O.F. Müller) Kützing (SMG-12-29); 
Codium adhaerens C. Agardh (SMG-12-28); Cys-
toseira humilis Schousboe ex Kützing (SMG-12-
26); Fucus spiralis Linnaeus (SMG-13-04); Ge-
lidium microdon Kϋtzing (SMG-13-03); Os-
mundea pinnatifida (Hudson) Stackhouse (SMG-
13-02); Padina pavonica (Linnaeus) Thivy 
(SMG-13-13); Porphyra sp. C. Agardh (SMG-14-
03); Pterocladiella capillacea (S.G. Gmelin) San-
telices & Hommersand (SMG-13-05); Ulva com-
pressa Linnaeus (SMG-13-15); Ulva rigida C. 
Agardh (SMG-13-12) and Sargassum cymosum 
C. Agardh (SMG-12-27). 
 
MACROALGAE SAMPLE PREPARATION 
Within 24 h of collection the macroalgae samples 
were first washed in seawater to remove encrust-
ing material and epiphytes, carefully rinsed with 
distilled water to remove salts and then air-dried 
and stored in an air-tight container in a freezer (-
80 °C) until further analysis. Prior to the analyti-
cal procedures, the samples were defrosted and 
dried at 45 °C during 48 h (avoiding overheating 
that could lead to oxidation). Dried triplicate 
samples were grounded into a fine powder, re-
dried at 40 °C and stored in desiccators at a re-
frigerated temperature. 
 
 
 
 
 
  
        
Anti-ACE activity from macroalgae of the Azores  
 13 
ENZYME SCREENING FOR THE ESTIMA-
TION OF THE HIGHER NUMBER OF            
PEPTIDES USING FUCUS SPIRALIS 
Five grams of Fucus spiralis was suspended in 
100 mL of distilled water and then homogenized 
with an Ultra-turrax T50 at 6.000 rpm for 10 min. 
Five milligrams of each protease were individual-
ly added to 10 mL of the homogenate, adjusting 
substrate/enzyme ratio to 100:1 (w/w) and the 
mixtures were incubated for 20 h at an appropri-
ated pH and temperature for each enzyme reac-
tion, using the conditions suggested by the manu-
facturer. After hydrolysis, the samples were heat-
ed for 15 min in boiling water in order to inacti-
vate the proteases. The precipitates were removed 
by centrifugation (1100 x g) at 4 °C for 10 min. 
The supernatants were concentrated and lyophi-
lized to obtain powder products that were used for 
the number of peptides determination using 
HPLC analysis under the following conditions: 
reverse-phase Zorbax Eclipse XDB-C18 column 
(4.6 x 150 mm i.d., 5 µm) (Agilent Technologies, 
USA) using a linear gradient of phase A - 0.1% 
TFA in water and phase B - 0.1% TFA in acetoni-
trile (t = 0 min - 0% B and t = 60 min - 40% B) at 
a flow rate of 1 mL/min and detection by UV at 
220 nm. 
 
PREPARATION OF MACROALGAE ENZY-
MATIC HYDROLYSATES FOR PRODUC-
TION OF ACE INHIBITORY PEPTIDES 
Twenty grams of the macroalgae samples were 
suspended in 300 mL of distilled water, homoge-
nized with an Ultra-turrax T50 at 6.000 rpm for 
10 min and then hydrolysed by proteolytic active 
enzymes (pepsin and bromelain) using the same 
reaction conditions described above. The homog-
enates were concentrated until an approximate 
volume of 150 mL and immediately transferred to 
a 10,000 Da MWCO dialyzing tube. Each perme-
ate was concentrated, lyophilized and kept at -80 
°C for the ACE inhibitory activity determination. 
 
DETERMINATION OF ACE INHIBITORY 
ACTIVITY 
For the assay, 80 µL of the enzymatic hydrolysate 
solution was pre-incubated at 37 °C for 5 min 
with 20 µL ACE (2 mU/mL) enzyme. The mix-
ture was subsequently incubated at the same tem-
perature with 200 µL of the substrate (5 mM 
HHL in 100 mM sodium trizma base containing 
300 mM NaCl at pH 8.3) during 60 min. The re-
action was terminated by adding 250 µL of 1 M 
HCl. The percentage of inhibition was determined 
by HPLC analysis. An aliquot of 10 µL from the 
reaction mixture was analyzed on a reverse-phase 
Ultrasphere C18 column (250 x 4.6 mm i.d., 5 µm) 
(Beckman Coulter, Miami, USA) using an iso-
cratic elution of MeOH:ACN:0.1% HCl 
(25:25:50 v/v/v) at a constant flow-rate of 0.5 
mL/min and HA and HHL were detected by UV 
at 228 nm. The percentage of ACE inhibition by 
macroalgae hydrolysate sample was calculated by 
the amount of the hippuric acid (HA) released 
from the substrate hippuryl-L-histidyl-L-leucine 
(HHL). The extent of inhibition was calculated as 
follows: 
ACE inhibition (%) = [1– (As – Ab)/C] x 100 
 
where As = HA peak area of the sample, Ab = 
Peak area of blank (no ACE or with ACE inhibi-
tor) and C = HA peak area (HHL plus ACE) 
without sample. 
 
The repeatability of the HA HPLC analysis was 
evaluated in intraday and interday measurements 
of the retention time by repeated injections (n = 
5). The recovery was calculated based on the dif-
ference between the total concentration deter-
mined in the spiked samples and the concentra-
tion observed in the non-spiked samples. 
 
STATISTICAL ANALYSIS 
All determinations were performed in triplicate 
and the results expressed as means ± standard 
deviations (SD). Statistical comparison was per-
formed by using one-way analysis of variance 
(ANOVA). A P-values of less than 0.05 (P < 
0.05) were considered to be statistically signifi-
cant. 
RESULTS AND DISCUSSION  
The HPLC methodology used to quantify the HA 
produced during the ACE-catalyzed reaction 
completely eliminates the interference from HHL 
during the quantification of the HA as compared 
with spectrophotometric  method of  Cushman &  
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Fig. 1. Representative HPLC chromatograms of the angiotensin-converting enzyme inhibition assay. a) More  
active enzymatic hydrolysate; b) Less active enzymatic hydrolysate; c) Control sample (without inhibitors).    
Chromatographic conditions as referred in methods. 
 
Cheung (1971). Complete baseline separation of 
HA and HHL was achieved by HPLC in isocratic 
elution conditions in less than 10 min under the 
analytical conditions described in methods (see 
Figure 1) showing a relative standard deviation 
(RSD) of 1.51% in multiple injections that repre-
sents a good repeatability. Another advantage of 
the HPLC method is the reduction of the time-
consuming process of HA extraction into ethyl 
acetate that is required by the standard Cushman 
& Cheung (1971) method and also the standard 
spectrophotometric assay requires at least 250 to 
500 µL of reaction mixture, compared to the 10 
µL used in HPLC assay. Therefore, the HPLC 
provides a simple, rapid and accurate method for 
the assay of ACE-catalyzed reactions. 
    The estimation of the proteolytic activity 
(number of peptides) derived from nine commer-
cial enzymes using F. spiralis revealed that pep-
sin and bromelain were the enzymes with higher 
proteolytic activity (Figure 2). 
    From the selected macroalgae species the bro-
melain hydrolysates derived from P. capillacea, 
Porphyra sp., F. spiralis, U. compressa, O. pin-
natifida and U. rigida presented an ACE inhibito-
ry activity similar and greater than 50% (ranging 
from 48.73% to 65.68%) (Figure 3). 
    The U. rigida exhibited the strongest anti-ACE 
activity (65.68 ± 0.72%) and the other Chloro-
phyta, U. compressa, presented the third highest 
anti-ACE activity (59.80 ± 0.95%). The Rhodo-
phyta O. pinnatifida presented the second highest 
anti-ACE activity (62.59 ± 1.60%) and the other 
red algal species showed lower activity (48.73 ± 
1.58% and 50.96 ± 1.82% for P. capillacea and 
Porphyra sp., respectively). The Heterokonto-
phyta F. spiralis, the only active of the selected 
brown  algae,  presented  the  fourth highest  anti- 
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Fig. 2. HPLC estimation for the proteolytic activity (number of peptides) derived from different commercial 
enzymes using the Azorean macroalgae Fucus spiralis. Chromatographic conditions as referred in methods; * 
Streptomyces griseus, ** Bacillus licheniformis. 
 
           
Fig. 3. Angiotensin-converting enzyme (ACE) inhibitory activity (%) of six selected Azorean macroal-
gae enzymatic hydrolysates. Algal protein not hydrolyzed was used for control. Data are mean ± SD of 
triplicate experiments. 
 
ACE activity (56.77 ± 1.80%). Remarkable ACE 
inhibitory activities of enzymatic hydrolysates 
from some macroalgae have also been reported 
by other authors, especially from brown and red 
algal species (e.g. Sato et al. 2002; Athukorala & 
Jeon 2005; Qu et al. 2010). From these studies, 
Qu et al. (2010) reported for Porphyra yezoensis 
55% of ACE inhibition that is similar to the value 
obtained for the studied Porphyra sp. (ca 51%). 
Research by Cha et al. (2006a,b), but using crude 
extracts from Korean Porphyra tenera, Ptero-
cladiella capillacea, Ulva conglobata and U.  
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pertusa, also reported ACE inhibition but much 
lower values than the ones obtained for the same 
genus in the present study. These results empha-
size the importance of the enzymatic hydrolysis 
in the process of ACE inhibitory activity. 
    In conclusion, this study shows a high activity 
in six Azorean macroalgae suggesting they can be 
excellent sources of ACE inhibitors, with poten-
tial pharmaceutical and nutraceutical applications. 
Therefore, purification and characterization of 
their ACE inhibitory peptides from the more  
potent hydrolysates is already in progress. 
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